SecBot SecBot
6-K ·Filed Jun 3, 2026

ARGX

ARGENX SE
BULLISH
Impact 5/10
Horizonweeks Processed5mo ago SEC0001104659-26-069786
Notable filing: 6-K
Actionable Insight ▲ Bullish

The data are incrementally positive but from open-label extensions, not randomized controlled trials. The key catalysts are the Phase 3 ALKIVIA topline in Q3 2026 and UNITY in H2 2027. Traders should monitor for potential stock moves around those readouts. Near-term, the EULAR data alone are unlikely to drive sustained re-rating without confirmatory Phase 3 results.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$813.14
T+0 close · Jun 3, 2026 · via day close
Latest settled
+30.22%
T+60 · $1,058.90
Vs SPY
+27.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $813.14entry
  2. T+1 · 6mo ago +3.58%α +3.18% · $842.27
  3. T+5 · 5mo ago +6.03%α +9.85% · $862.18
  4. T+20 · 5mo ago +15.56%α +16.56% · $939.68
  5. T+60 · 3mo ago +30.22%α +27.72% · $1,058.90

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Argenx presented new long-term data for efgartigimod in myositis (ALKIVIA+ open-label extension) and Sjogren's disease (RHO+ extension) at EULAR 2026, showing sustained clinical benefit and consistent safety. Topline Phase 3 results for myositis (ALKIVIA) are expected in Q3 2026, and for Sjogren's (UNITY) in H2 2027. The data reinforce the FcRn mechanism in rheumatology but are interim open-label results, not pivotal.

Key Facts

  • ALKIVIA+ myositis data at 52 weeks: 37.5% of continuous efgartigimod patients maintained major TIS improvement; mean TIS 52.19 for continuous arm, 49.62 for placebo-switch arm.
  • RHO+ Sjogren's data at 72 weeks: median ClinESSDAI scores low at 2.5 (efgartigimod arm) and 2.0 (placebo-switch arm); maintenance of response on biweekly dosing.
  • Cross-indication safety analysis: consistent profile across 834 treated patients and >1,300 patient-years of follow-up.
  • Topline Phase 3 ALKIVIA (myositis) results expected Q3 2026; Phase 3 UNITY (Sjogren's) topline expected H2 2027.
  • Phase 2 eSScape study design for systemic sclerosis presented; no data yet.

Financial Impact

No financial figures reported. Positive clinical data supports pipeline value for efgartigimod in two new indications (myositis, Sjogren's) with combined addressable market potentially in the billions, but no revenue or cost estimates provided.

pipeline valuefuture revenue potential

Risk Factors

  • Phase 3 ALKIVIA (myositis) may fail to meet primary endpoint despite Phase 2 signal.
  • Phase 3 UNITY (Sjogren's) topline not expected until H2 2027; long wait with binary risk.
  • Open-label extension data are subject to selection bias and lack placebo control.
  • Competition from other FcRn blockers and alternative therapies in rheumatology.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-069786
Document: tm2616678d1_6k.htm0001104659-26-069786
Document: 0001104659-26-069786-index-headers.html0001104659-26-069786
Document: 0001104659-26-069786-index.html0001104659-26-069786
Document: 0001104659-26-069786.txt0001104659-26-069786

Track record

23 reports on ARGX

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +20.35% at T+20 after the Aug 6, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  2. Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $950.95 +6.28% settles Dec 4
  5. Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $950.95 +5.91% settles Nov 27
  6. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $950.95 +8.59% settles Nov 19
  7. Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $950.95 +15.18% ▲ +15.18% +18.64% vs SPY
  8. Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $950.95 +16.16% ▲ +13.77% +19.06% vs SPY
  9. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $950.95 −2.03% ▼ −10.21% −10.87% vs SPY
  10. Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $950.95 −3.36% ▼ −16.81% −18.93% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026